lycoprotein (P-gp).
Canagliflozin; Metformin: Use caution when administering velpatasvir with canagliflozin. Taking these medications together may increase the plasma concentrations of both drugs, potentially resulting in adverse events. Both drugs are substrates and inhibitors of the drug transporter P-glycoprotein (P-gp).
Captopril: Use caution when administering velpatasvir with captopril. Taking these drugs together may increase the plasma concentrations of velpatasvir, potentially resulting in adverse events. Velpatasvir is a substrate of the drug transporter P-glycoprotein (P-gp); captopril is an inhibitor of P-gp.
Captopril; Hydrochlorothiazide, HCTZ: Use caution when administering velpatasvir with captopril. Taking these drugs together may increase the plasma concentrations of velpatasvir, potentially resulting in adverse events. Velpatasvir is a substrate of the drug transporter P-glycoprotein (P-gp); captopril is an inhibitor of P-gp.
Carbamazepine: Avoid coadministration of sofosbuvir with inducers of P-glycoprotein (P-gp), such as carbamazepine. Taking these drugs together may decrease sofosbuvir plasma concentrations, potentially resulting in loss of antiviral efficacy. Avoid coadministration of velpatasvir with inducers of P-glycoprotein (P-gp) and CYP 3A4 and 2B6 isoenzymes, such as carbamazepine. Taking these drugs together may significantly decrease velpatasvir plasma concentrations, potentially resulting in loss of antiviral efficacy. Velpatasvir is metabolized by P-gp and CYP3A4 and 2B6.
Carvedilol: Use caution when administering velpatasvir with carvedilol. Taking these medications together may increase the plasma concentrations of both drugs, potentially resulting in adverse events. Both drugs are substrates and inhibitors of the drug transporter P-glycoprotein (P-gp). Coadministration of sofosbuvir and carvedilol may result in elevated sofosbuvir plasma concentrations. Sofosbuvir is a substrate for the drug transporter P-glycoprotein (P-gp); carvedilol is a P-gp inhibitor. According to the manufacturer, no dosage adjustments are required when sofosbuvir is administered concurrently with P-gp inhibitors; however, if these drugs are given together, consider increased monitoring for potential adverse effect.
Chloramphenicol: Use caution when administering velpatasvir with chloramphenicol. Taking these drugs together may increase velpatasvir plasma concentrations, potentially resulting in adverse events. Chloramphenicol is a potent CYP3A4 inhibitor; velpatasvir is a substrate of CYP3A4.
Cimetidine: H2-blockers may be administered simultaneously with or 12 hours apart from velpatasvir. H2-blocker doses should not exceed doses comparable to famotidine 40 mg twice daily. Velpatasvir solubility decreases as pH increases; therefore, drugs that increase gastric pH are expected to decrease the concentrations of velpatasvir, potentially resulting in loss of antiviral efficacy.
Ciprofloxacin: Use caution when administering velpatasvir with ciprofloxacin. Taking these drugs together may increase velpatasvir plasma concentrations, potentially resulting in adverse events. Ciprofloxacin is a weak CYP3A4 inhibitor; velpatasvir is a substrate of CYP3A4.
Clarithromycin: Use caution when administering velpatasvir with clarithromycin. Taking these medications together may increase the plasma concentrations of both drugs, potentially resulting in adverse e |
